K. Brian Matlock

KBM jpg

Brian Matlock is a seasoned senior corporate counsel and former law firm partner with extensive experience in corporate law, securities regulation, mergers & acquisitions, technology transactions, intellectual property, and complex litigation. He has successfully saved clients millions in litigation costs and provided strategic advice to private equity firms, venture capitalists, tech companies, and closely held businesses. His expertise has led to favorable outcomes in negotiations, settlements, arbitrations, and litigation, securing millions in client savings and verdicts.

Recently, Brian served as general counsel for Amphastar Pharmaceuticals, managing FDA New Drug Applications, major litigation, and corporate compliance. He also worked as senior counsel with Intel Corporation on a $10B spin-out transaction, driving significant cost savings and generating substantial licensing revenue.

In addition to his legal expertise, Brian has a strong background in technology commercialization and licensing within university settings and has played a pivotal role in securing up to $60MM in equity funding for startups. His earlier career includes engineering, business development, and R&D management roles with global manufacturers, where he was recognized as a top performer.

Brian has led legal teams in high-stakes matters, including saving a client over $1MM in lost profits and securing $600K in new revenue in a trade secrets mediation. He has advised C-level executives and Fortune 500 managers on dispute resolution, licensing, R&D, acquisitions, international business, and capital finance. His work also includes closing numerous exclusive licensing and research agreements at the University of Missouri-Columbia and leading legal efforts as general counsel at Shift Pharmaceuticals and ImpeDx Diagnostics in Kansas City.


Areas of Practice:
  • Intellectual Property Law
  • Corporate Law
  • Copyright Law
  • Patent Law
  • Trademark Law
  • Business Law
  • Startup Law
Education:
  • Washington University in St. Louis
  • University of the Pacific - McGeorge School of Law
Languages:
  • English
  • German

Dr. Dariush Adli Writes for Bloomberg Law and Reviews the Impact of the Mallinckrodt Decision on Patent Protections

November 6, 2019

ADLI’s founder, president, and intellectual property leader, Dr. Dariush Adli, wrote an article for Bloomberg Law on the impacts of the recent Mallinckrodt decision on patent protections. In particular, the piece discusses the…

ADLI Cannabis Facilitates $1M Cross-Border CBD Business All-Share Transaction

October 4, 2019

ADLI’s Cannabis Group (also known as the Vice Group) was successful in representing ADLI Cannabis client, 2Rise Naturals in a $1M cross-border transaction. The deal is an all-share transaction that will result in…

ADLI Cannabis Sponsoring the Cannabis World Congress & Business Exposition Industry Party

September 27, 2019

The Cannabis World Congress & Business Exposition (CWCB) is the leading business-to-business trade show event for the legalized cannabis industry. It is held three times per year in the most…